Article
Pharmacology & Pharmacy
Fangfang Cai, Huangru Xu, Daolong Zha, Xiaoyang Wang, Ping Li, Shihui Yu, Yingying Yao, Xiaoyao Chang, Jia Chen, Yanyan Lu, Zi-Chun Hua, Hongqin Zhuang
Summary: AK2 regulates tumor cell metastasis in lung adenocarcinoma, with its high expression associated with poor patient survival; AK2 is closely related to the migration and invasion ability of lung adenocarcinoma cells; AK2 may regulate epithelial-mesenchymal transition through Smad-related signaling pathways.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, Research & Experimental
Zhanjun Chen, Leyang Xiang, Longhai Li, Huohui Ou, Yinghao Fang, Yuyan Xu, Qin Liu, Zhigang Hu, Yu Huang, Xianghong Li, Dinghua Yang
Summary: The study revealed that linc00261 suppressed EMT and stem-like traits in HCC cells by inhibiting TGF-beta1/SMAD3 signaling.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Medicine, Research & Experimental
Ning Zhao, Minwei He, Wei Chen, Peng Jin, Lulu Cao, Jinhai Deng, Xu Cheng, Lu Wang
Summary: Our study identified FAM96A as a crucial regulator of tumor metastasis and epithelial-mesenchymal transition (EMT) by inhibiting the TGF-beta signaling pathway.
Article
Cell Biology
Chenglai Dong, Kaiqin Wu, Shaorui Gu, Wenli Wang, Shiliang Xie, Yongxin Zhou
Summary: The study revealed the critical role of PTBP3 in LUAD, with its high expression associated with poor prognosis. PTBP3 mediates TGF-beta-induced EMT and metastasis by activating the Smad pathway for transcription. This research provides a new potential therapeutic target for the treatment of LUAD.
Article
Oncology
Tetsuro Watabe, Kazuki Takahashi, Kristian Pietras, Yasuhiro Yoshimatsu
Summary: Tumor cells evolve through interactions with various cell types in the tumor microenvironment. Endothelial cells (ECs), as important players in tumor angiogenesis, also contribute to tumor progression and metastasis through a process called endothelial-mesenchymal transition (EndoMT). EndoMT, mediated by cytokines like TGF-beta, is involved in multiple steps of tumor progression and can be targeted as a therapeutic strategy.
SEMINARS IN CANCER BIOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Jitka Soukupova, Andrea Malfettone, Esther Bertran, Maria Isabel Hernandez-Alvarez, Irene Penuelas-Haro, Francesco Dituri, Gianluigi Giannelli, Antonio Zorzano, Isabel Fabregat
Summary: EMT induced by TGF-beta in HCC cells reprograms lipid metabolism to facilitate the utilization of FFA and the entry of acetyl-CoA into the TCA cycle, to sustain the elevated requirements of energy linked to this process.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Young Y. Jung, Arunachalam Chinnathambi, Tahani A. Alahmadi, Sulaiman A. Alharbi, Alan P. Kumar, Gautam Sethi, Kwang S. Ahn
Summary: This study demonstrates that Fangchinoline (FCN) can inhibit the epithelial-mesenchymal transition (EMT) in human colon cancer cells, thereby reducing their metastatic and invasive capacities. In addition, FCN can suppress multiple cell signaling pathways, including c-Met/PI3K/Akt/mTOR and Wnt/β-catenin pathways. Therefore, FCN has the potential to be a novel antimetastatic agent against colon cancer.
JOURNAL OF CELLULAR BIOCHEMISTRY
(2022)
Review
Oncology
Ester Gonzalez-Sanchez, Javier Vaquero, Maite G. Fernandez-Barrena, Juan Jose Lasarte, Matias A. Avila, Pablo Sarobe, Maria Reig, Mariona Calvo, Isabel Fabregat
Summary: TGF-beta signaling plays a dual role in HCC, acting as a tumor suppressor at early stages but promoting progression later on. It can also impact the tumor microenvironment and drive immune evasion of cancer cells. Targeting the TGF-beta pathway may be an effective therapeutic option for HCC, but biomarkers are crucial for patient selection.
Article
Plant Sciences
Shu-Fang Huang, Yu-Lun Wang, Jih-Jung Chen, Yaw-Bin Huang, Shun-Ban Tai, Chih-Ling Chung, Chun-Lin Chen
Summary: The study demonstrates that Garcimultiflorone K (GMK) extracted from Garcinia multiflora inhibits TGF-beta signaling in hepatocellular carcinoma cells, attenuating metastasis and the disease-promoting effects of epithelial-mesenchymal transition (EMT). GMK was found to suppress TGF-beta-induced cellular responses such as Smad protein phosphorylation, cell migration, and extracellular matrix production.
Article
Cell Biology
Yang-Zhi Hu, Zhi-Li Hu, Tian-You Liao, Yuan Li, Yun-Long Pan
Summary: This study aimed to investigate the effects of lncRNA SND1-IT1, miR-124, and COL4A1 gene on TGF-beta 1-induced EMT in gastric cancer (GC). Through the analysis of tissue samples and experiments on HGC-27 cells, the results demonstrated that TGF-beta 1 can regulate cancer cell migration, invasion, and stimulate EMT through the SND1-IT1/miR-124/COL4A1 axis in GC.
CELL DEATH DISCOVERY
(2022)
Article
Oncology
Hsin-Yi Chen, Shu-Jou Chan, Xinxin Liu, An-Chi Wei, Ru-In Jian, Kuan-Wei Huang, Yaw-Dong Lang, Jou-Ho Shih, Chun-Chieh Liao, Chiu-Lin Luan, Yu-Tung Kao, Shang-Yin Chiang, Pei-Wen Hsiao, Yuh-Shan Jou, Yunching Chen, Ruey-Hwa Chen
Summary: This study identifies the lncRNA Smyca as an oncogene that promotes poor prognosis in multiple cancer types. Smyca enhances tumor metabolic reprogramming, migration, invasion, cancer stemness, metastasis, and chemoresistance by potentiating TGF-beta/Smad signaling and c-Myc-mediated transcription. Targeting Smyca prevents metastasis and overcomes chemoresistance.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Ensieh M. Poursani, Daniele Mercatelli, Prahlad Raninga, Jessica L. Bell, Federica Saletta, Felix V. Kohane, Daniel P. Neumann, Ye Zheng, Jourdin R. C. Rouaen, Toni Rose Jue, Filip T. Michniewicz, Piper Schadel, Erin Kasiou, Maria Tsoli, Giuseppe Cirillo, Shafagh Waters, Tyler Shai-Hee, Riccardo Cazzoli, Merryn Brettle, Iveta Slapetova, Maria Kasherman, Renee Whan, Fernando Souza-Fonseca-Guimaraes, Linda Vahdat, David Ziegler, John G. Lock, Federico M. Giorgi, KumKum Khanna, Orazio Vittorio
Summary: Metastatic cancer cells use Epithelial-mesenchymal-transition (EMT) to enhance migration, invasion, and treatment resistance, and elevated levels of copper are implicated in cancer progression and metastasis. Copper chelation therapy can inhibit metastasis by reducing TGF-beta levels and EMT signaling, making it a potentially effective therapeutic approach for targeting TGF-beta and inhibiting EMT in various cancers.
CELL AND BIOSCIENCE
(2023)
Article
Biochemistry & Molecular Biology
Juan Kong, Di Li, Shidong Zhang, Huixia Zhang, Yuanyuan Fu, Bo Qian, Chunhua Bei, Shengkui Tan, Xiaonian Zhu
Summary: Okadaic acid (OA) has been found to promote the epithelial-mesenchymal transition (EMT) process of hepatocellular carcinoma cells, enhancing their invasion and migration abilities while decreasing the activity of protein phosphatase 2A (PP2A). This indicates that OA plays a role in promoting metastasis of HCC.
JOURNAL OF CELLULAR BIOCHEMISTRY
(2021)
Article
Cell Biology
Daiqin Luo, Xianlin Zeng, Shuling Zhang, Daohong Li, Zhimei Cheng, Yun Wang, Jinhua Long, Zuquan Hu, Shiqi Long, Jing Zhou, Shuai Zhang, Zhu Zeng
Summary: Metastasis is the main cause of death among breast cancer patients. Little progress has been made in improving the treatment of breast cancer metastases, particularly triple-negative breast cancer (TNBC). The extracellular matrix plays a crucial role in tumor growth and metastasis. This study evaluates the efficacy of Pirfenidone (PFD) on TNBC cells and its anti-tumor effects in a xenograft tumor model.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Yong-Hwi Kang, Jing-Hua Wang, Jin-Seok Lee, Nam-Hun Lee, Chang-Gue Son
Summary: Colorectal cancer is the second most lethal malignancy worldwide, and its high mortality rate is largely due to cancer metastasis. Suppression of epithelial-to-mesenchymal transition (EMT) has emerged as a promising strategy for treating metastatic cancer. This study evaluated the antimetastatic effect of Coptidis Rhizoma, a traditional Chinese medicine, on drug-resistant colon cancer cells and found that it inhibits EMT through the TGF-beta signaling pathway.
FRONTIERS IN PHARMACOLOGY
(2022)